サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1439320

コンパニオン診断 - 世界市場の考察、競合情勢、市場予測（2030年）

Companion Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
コンパニオン診断 - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のコンパニオン診断の市場規模は、2023年に59億1,000万米ドル、2030年までに118億9,000万米ドルに達し、2024年～2030年の予測期間にCAGRで12.32％の成長が見込まれます。市場の成長は主に、世界中でのがん患者の急激な増加によるものです。加えて、精密医療に関する患者の意識の高まりや、精密医療の開発に関するメーカーの関心の高まりがコンパニオン診断の需要を高めています。さらに、がん以外の疾患に対するコンパニオン診断の開発に向けた研究開発の増加や、市場におけるさまざまなコンパニオン診断の承認や発売の増加は、予測期間（2024年～2030年）に世界のコンパニオン診断市場を拡大すると予測される主な要因の一部です。

コンパニオン診断の市場力学

コンパニオン診断市場は、がん患者における精密医療または個別化医療への選好の高まりにより、かなりの成長が見込まれます。精密医療は、がん患者に対する薬剤の選択や標的治療を改善し、副作用を軽減する可能性があるためです。さらに、個別化医療は、がんの治療レジメンをより費用対効果の高いものにすることで、患者コンプライアンスを向上させます。コンパニオン診断は効果予測バイオマーカーアッセイであり、健康転帰を改善するために遺伝子やゲノムデータを活用する精密医療の発展において重要な役割を果たします。このように、個別化医療への選好の高まりは、コンパニオン診断市場を拡大すると考えられます。

さらに、精密医療やがんのバイオマーカー検査に関する認知度を高める政府や組織の取り組みは、精密医療の採用を増加させる可能性が高く、結果としてコンパニオン診断の需要を高め、市場を活性化させることが予測されます。例えば2022年11月、肺がんに焦点を当てた主な非営利団体であるLUNGevity Foundationは、非小細胞肺がん（NSCLC）における包括的なバイオマーカー検査に対する認識を高めることを目的としたNo One Missedキャンペーンの一環として、1年間にわたる「#KnowYourBiomarker」ソーシャルメディア活動を開始しました。

さらに、アルツハイマー病やハンチントン病など、がん以外のさまざまな疾患に対するコンパニオン診断の開発を主要メーカーが重視するようになったことで、そのような疾患の管理と治療を支援し、患者の転帰を改善するコンパニオン診断ツールの採用が増加することも予測されます。例えば2019年11月、バイオテクノロジーのブランドであるAsuragenは、ハンチントン病のコンパニオン診断を開発するためにWave Life Sciencesと提携しました。

したがって、上記のすべての要因が、今後数年間に世界のコンパニオン診断市場を増強すると予測されます。

しかし、コンパニオン診断の高いコストや、多くの国での限られた償還、これらの機器の承認に関する規制の複雑性などが、コンパニオン診断市場の成長を抑制すると予測されています。

また、COVID-19パンデミックの発生により、コンパニオン診断市場の成長は鈍化しています。これは、ロックダウンの実施、需要とサプライチェーンの制約によるものです。さらに、パンデミック中、世界中の医療システムのガイドラインは一時的にCOVID-19患者の管理に全力を注いでいました。例えば、National Cancer Institute（2022）が提供したデータによると、COVID-19パンデミックによるロックダウン規制に関連する課題のほかに、2020年3月だけでも、COVID-19によって800件以上の肺がん検診の予約延期が余儀なくされたことが確認されています。しかし、世界中で数多くのCOVID-19ワクチンが承認および投与されたおかげで、医療サービスを含むさまざまな領域での活動再開に大きな向上が見られ、コンパニオン診断市場の健全な回復期への道が開かれました。

当レポートでは、世界のコンパニオン診断市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 コンパニオン診断市場レポートのイントロダクション

第2章 コンパニオン診断市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 コンパニオン診断市場の主な要因の分析

  • コンパニオン診断市場の促進要因
    • 世界中でのがん患者の増加
    • 精密医療に関する需要と意識の高まり
    • さまざまなコンパニオン診断製品の承認と発売の増加
    • コンパニオン診断分野における研究開発の高まり
  • コンパニオン診断市場の抑制要因と課題
    • コンパニオン診断の高いコスト、多くの国での限られた償還
    • コンパニオン診断製品の承認に向けた複雑な規制プロセス
  • コンパニオン診断市場の機会
    • 低中所得国における市場機会
    • さまざまな非がん疾患におけるコンパニオン診断の機会

第5章 コンパニオン診断のポーターのファイブフォース分析

第6章 コンパニオン診断市場に対するCOVID-19の影響分析

第7章 コンパニオン診断市場のレイアウト

  • タイプ別
    • 製品
    • サービス
  • 技術別
    • 免疫組織化学
    • 次世代シーケンシング（NGS）
    • ポリメラーゼ連鎖反応（PCR）
    • その他
  • 適応症別
    • 肺がん
    • 乳がん
    • 大腸がん
  • エンドユーザー別
    • 病院
    • 診断検査室
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 コンパニオン診断：世界の企業シェア分析 - 主要3～5社

第9章 コンパニオン診断の企業と製品のプロファイル

  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd
  • Myriad Genetics, Inc.
  • Abbott Laboratories.
  • QIAGEN
  • BIOMERIEUX
  • Guardant Health Inc.
  • Illumina, Inc.
  • Leica Biosystems
  • Thermo Fisher Scientific Inc.
  • Almac Group
  • NeoGenomics Laboratories.
  • Invitae Corporation
  • 3D Medicines Corporation
  • ASURAGEN, INC. (Biotechne)
  • Invivoscribe, Inc.
  • Amoy Diagnostics Co., Ltd.
  • Laboratory Corporation of America® Holdings.
  • SAGA Diagnostics
  • Pillar Biosciences, Inc.

第10章 KOLの見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis on Companion Diagnostics Market
  • Table 3: Companion Diagnostics Market Analysis in Global (2021-2030)
  • Table 4: Companion Diagnostics Market Analysis in Global by Product Type (2021-2030)
  • Table 5: Companion Diagnostics Market Analysis in Global by Application (2021-2030)
  • Table 6: Companion Diagnostics Market Analysis in Global by Indication (2021-2030)
  • Table 7: Companion Diagnostics Market Analysis in Global by End User (2021-2030)
  • Table 8: Companion Diagnostics Market Analysis in Global by Geography (2021-2030)
  • Table 9: Companion Diagnostics Market Analysis in North America (2021-2030)
  • Table 10: Companion Diagnostics Market Analysis in North America by Country (2021-2030)
  • Table 11: Companion Diagnostics Market Analysis in the US (2021-2030)
  • Table 12: Companion Diagnostics Market Analysis in Canada (2021-2030)
  • Table 13: Companion Diagnostics Market Analysis in Mexico (2021-2030)
  • Table 14: Companion Diagnostics Market Analysis in Europe (2021-2030)
  • Table 15: Companion Diagnostics Market Analysis in Europe by Country (2021-2030)
  • Table 16: Companion Diagnostics Market Analysis in France (2021-2030)
  • Table 17: Companion Diagnostics Market Analysis in Germany (2021-2030)
  • Table 18: Companion Diagnostics Market Analysis in the UK (2021-2030)
  • Table 19: Companion Diagnostics Market Analysis in Italy (2021-2030)
  • Table 20: Companion Diagnostics Market Analysis in Spain (2021-2030)
  • Table 21: Companion Diagnostics Market Analysis in Russia (2021-2030)
  • Table 22: Companion Diagnostics Market Analysis in Rest of Europe (2021-2030)
  • Table 23: Companion Diagnostics Market Analysis in Asia-Pacific (2021-2030)
  • Table 24: Companion Diagnostics Market Analysis in Asia-Pacific by Country (2021-2030)
  • Table 25: Companion Diagnostics Market Analysis in China (2021-2030)
  • Table 26: Companion Diagnostics Market Analysis in Japan (2021-2030)
  • Table 27: Companion Diagnostics Market Analysis in India (2021-2030)
  • Table 28: Companion Diagnostics Market Analysis in Australia (2021-2030)
  • Table 29: Companion Diagnostics Market Analysis in South Korea (2021-2030)
  • Table 30: Companion Diagnostics Market Analysis in Rest of Asia-Pacific (2021-2030)
  • Table 31: Companion Diagnostics Market Analysis in Rest of World (2021-2030)
  • Table 32: Companion Diagnostics Market Analysis in Rest of World by Region (2021-2030)
  • Table 33: Companion Diagnostics Market Analysis in the Middle East (2021-2030)
  • Table 34: Companion Diagnostics Market Analysis in Africa (2021-2030)
  • Table 35: Companion Diagnostics Market Analysis in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis on Companion Diagnostics Market
  • Figure 3: Companion Diagnostics Market Analysis in Global (2021-2030)
  • Figure 4: Companion Diagnostics Market Analysis in Global by Type (2021-2030)
  • Figure 5: Companion Diagnostics Market Analysis in Global by Technology (2021-2030)
  • Figure 6: Companion Diagnostics Market Analysis in Global by Indication (2021-2030)
  • Figure 7: Companion Diagnostics Market Analysis in Global by End User (2021-2030)
  • Figure 8: Companion Diagnostics Market Analysis in Global by Geography (2021-2030)
  • Figure 9: Companion Diagnostics Market Analysis in North America (2021-2030)
  • Figure 10: Companion Diagnostics Market Analysis in North America by Country (2021-2030)
  • Figure 11: Companion Diagnostics Market Analysis in the US (2021-2030)
  • Figure 12: Companion Diagnostics Market Analysis in Canada (2021-2030)
  • Figure 13: Companion Diagnostics Market Analysis in Mexico (2021-2030)
  • Figure 14: Companion Diagnostics Market Analysis in Europe (2021-2030)
  • Figure 15: Companion Diagnostics Market Analysis in Europe by Country (2021-2030)
  • Figure 16: Companion Diagnostics Market Analysis in France (2021-2030)
  • Figure 17: Companion Diagnostics Market Analysis in Germany (2021-2030)
  • Figure 18: Companion Diagnostics Market Analysis in the UK (2021-2030)
  • Figure 19: Companion Diagnostics Market Analysis in Italy (2021-2030)
  • Figure 20: Companion Diagnostics Market Analysis in Spain (2021-2030)
  • Figure 21: Companion Diagnostics Market Analysis in Russia (2021-2030)
  • Figure 22: Companion Diagnostics Market Analysis in Rest of Europe (2021-2030)
  • Figure 23: Companion Diagnostics Market Analysis in Asia-Pacific (2021-2030)
  • Figure 24: Companion Diagnostics Market Analysis in Asia-Pacific by Country (2021-2030)
  • Figure 25: Companion Diagnostics Market Analysis in China (2021-2030)
  • Figure 26: Companion Diagnostics Market Analysis in Japan (2021-2030)
  • Figure 27: Companion Diagnostics Market Analysis in India (2021-2030)
  • Figure 28: Companion Diagnostics Market Analysis in Australia (2021-2030)
  • Figure 29: Companion Diagnostics Market Analysis in South Korea (2021-2030)
  • Figure 30: Companion Diagnostics Market Analysis in Rest of Asia-Pacific (2021-2030)
  • Figure 31: Companion Diagnostics Market Analysis in Rest of World (2021-2030)
  • Figure 32: Companion Diagnostics Market Analysis in Rest of World by Region (2021-2030)
  • Figure 33: Companion Diagnostics Market Analysis in the Middle East (2021-2030)
  • Figure 34: Companion Diagnostics Market Analysis in Africa (2021-2030)
  • Figure 35: Companion Diagnostics Market Analysis in South America (2021-2030)
  • Figure 36: Market Drivers
  • Figure 37: Market Barriers
  • Figure 38: Market Opportunities
  • Figure 39: PORTER's Five Force Analysis
目次
Product Code: DIMDCL0112

Companion Diagnostics Market By Type (Product [Assays, Kits & Reagents And Instruments], Services), By Technology (Immunohistochemistry (Ihc), Next-Generation Sequencing (Ngs), Polymerase Chain Reaction (Pcr), Others), By Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Others), By End-User (Hospitals, Diagnostic Labs, Others), by geography, is expected to grow at a noteworthy CAGR till 2030 owing to the increase in the cancer burden across the globe and growing focus on personalized medicines

The global companion diagnostics market was valued at USD 5.91 billion in 2023, growing at a CAGR of 12.32% during the forecast period from 2024 to 2030, to reach USD 11.89 billion by 2030. The increase in the market for companion diagnostics is predominantly owing to an exponential rise in cancer cases across the globe. Additionally, the rise in awareness regarding precision medicine among the patient population as well as the growing focus of the manufacturers concerning the development of precision medicine has bolstered the demand for companion diagnostics. Furthermore, an increase in research and development for developing companion diagnostics for non-cancer disorders, and growing approvals and launches of various companion diagnostic products in the market, among others are some of the key factors anticipated to augment the global market for companion diagnostics during the forecast period (2024-2030).

Companion Diagnostics Market Dynamics:

The market for companion diagnostics is projected to witness considerable growth due to the increase in preference for precision medicine or personalized medicine among cancer patients. This is because precision medicine has the potential to offer an improved medication selection and targeted therapy for cancer patients thereby reducing adverse effects. Moreover, personalized medicine increases patient compliance by making the treatment regimen for cancer more cost-effective. Companion diagnostics are predictive biomarker assays that play a significant role in the development of precision medicine which leverages genetic and genomic data to improve health outcomes. Thus, a growing preference for personalized medicine is likely to increase the market for companion diagnostics.

Furthermore, government, as well as organizations' initiatives to raise awareness regarding precision medicine and biomarker testing for cancer are likely to increase the adoption of precision medicine which in return is expected to raise the demand for companion diagnostics thus, fuelling the market. For instance, in November 2022, LUNGevity Foundation, a leading lung cancer-focused nonprofit organization, launched a year-long #KnowYourBiomarker social media initiative as part of the No One Missed campaign aimed at driving awareness of comprehensive biomarker testing in non-small cell lung cancer (NSCLC).

Additionally, a shift in the focus of key manufacturers on developing companion diagnostics for various non-cancer disorders such as Alzheimer's disorders, Huntington's disease, and others are also expected to increase the adoption of companion diagnostic tools to aid in the management and treatment of such diseases and improve patient outcomes. For instance, in November 2019, Asuragen, a biotechne brand partnered with Wave Life Sciences to develop companion diagnostics for Huntington's Disease.

Thus, all the above factors are expected to augment the global companion diagnostics market in the forthcoming years.

However, the high cost of companion diagnostics coupled with limited reimbursement in many countries and complex regulations for the approval of these devices are expected to impede the market growth for companion diagnostics.

Also, owing to the outbreak of the COVID-19 pandemic, the companion diagnostics market witnessed slow growth. This is due to the implementation of lockdown, and restrictions on demand & supply chain. Moreover, during the pandemic the healthcare system guidelines across the globe temporarily focused all their efforts on the management of COVID-19 patient, due to which the number of cancer screening were reduced. For instance, as per the data provided by the National Cancer Institute 2022, besides the challenges associated with the lockdown restrictions due to the COVID-19 pandemic, it was observed that in March 2020 alone, COVID-19 forced the postponement of more than 800 appointments for lung cancer screening. However, owing to the approval and administration of numerous COVID-19 vaccines across the globe, there was a significant improvement in the resumption of activities across various domains including healthcare services, thereby paving the way for a sound period of recovery for the companion diagnostics market.

Companion Diagnostics Market Segment Analysis:

Companion Diagnostics Market By Type (Product [Assays, Kits & Reagents and Instruments], Services), By Technology (Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Others), By Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Others), By End-User (Hospitals, Diagnostic Labs, Others), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the product type segment of the companion diagnostics market, the assays, kits & reagents subsegment is expected to hold a significant market share in the year 2023. The rise in collaboration among the companies focused on developing diagnostic products and giant pharmaceutical companies for developing companion diagnostics kits to improve cancer treatment and management is expected to augment the market for these product types. For instance, on August 05, 2022, Shanghai Henlius Biotech, Inc. entered into a Collaboration with Promega to Develop the Companion Diagnostic Kit for Henlius' Serplulimab MSI-H Solid Tumours Indication.

Furthermore, the rise in the focus on developing and launching companion diagnostic assays with advanced sequencing techniques and those which require non-invasive samples could also increase the demand for this segment. For instance, in August 2020, the US Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology (Guardant360 CDx assay) to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC).

Additionally, companies raising funds to develop companion diagnostic products and strengthen their portfolio to expand the market access are further projected to contribute to the segmental growth of the companion diagnostics market. For instance, in May 2018, Cergentis, a Dutch biotech company, secured a > Euro-1.2 million grant from the European Commission's Horizon 2020 program for the development of cancer companion diagnostics. The company planned to use the funds obtained to optimize and validate the TLA technology for the analysis of (FFPE) tumor biopsies.

Hence, the interplay of all the above-mentioned factors is projected to boost the companion diagnostics market in the upcoming years.

North America is expected to dominate the overall Companion Diagnostics Market:

Among all the regions, North America is expected to hold a major share in the overall Companion Diagnostics market in the year 2023 and will retain its market position during the forecast period. This is due to the rising prevalence and incidence of various cancers in the region. For instance, as per the 2020 data revealed by the GLOBOCAN, the new cancer cases reported in the US, Canada, and Mexico were 2,281,658; 2,74,364; and 1,95,499, respectively.

Moreover, favorable reimbursement policies, approval & launches of various companion diagnostic products in the region, various business expansion activities underwent by the companies present in the region, and others are some of the factors responsible for the companion diagnostics market.

For instance, in 2018, the Centers for Medicare & Medicaid Services (CMS) finalizes coverage of Next Generation Sequencing tests, ensuring enhanced access for cancer patients. The CMS believed when these tests are used as a companion diagnostic to identify patients with certain genetic mutations may benefit from the US Food and Drug Administration (FDA)-approved treatments.

Also, in April 2019, Agilent received an expanded FDA Approval for its companion diagnostic in NSCLC.

Hence, all the above-stated factors are projected to propel the regional market growth of companion diagnostics during the forecast period.

Companion Diagnostics Market Key Players:

Some of the key market players operating in the Companion Diagnostics market include Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Abbott Laboratories., QIAGEN, BIOMERIEUX, Guardant Health Inc., Illumina, Inc., Pillar Biosciences, Inc., Leica Biosystems, Thermo Fisher Scientific Inc., Almac Group, NeoGenomics Laboratories., Invitae Corporation, 3D Medicines Corporation, ASURAGEN, INC. (Biotechne), Invivoscribe, Inc., Amoy Diagnostics Co., Ltd., Laboratory Corporation of AmericaR Holdings., SAGA Diagnostics, and others.

Recent Developmental Activities in the Companion Diagnostics Market:

In March 2022, Myriad Genetics received FDA approval of BRACAnalysis? CDx as a companion diagnostic for Lynparza? in early breast cancer.

In October 2022, Agilent was granted the FDA approval for its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) as a companion diagnostics in identifying patients with early breast cancer (EBC) at high risk of disease recurrence, for whom adjuvant treatment with Verzenio? (abemaciclib) in combination with endocrine therapy is being considered.

In August 2022, Roche received FDA approval for the first companion diagnostic to identify dMMR solid tumor patients eligible for anti-PD-1 immunotherapy.

Key Takeaways from the Companion Diagnostics Market Report Study

  • Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Companion Diagnostics market.
  • Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened in the last 3 years
  • Key companies dominating the Global Companion Diagnostics Market.
  • Various opportunities available for the other competitor in the Companion Diagnostics Market space.
  • What are the top-performing segments in 2023? How these segments will perform in 2030.
  • Which are the top-performing regions and countries in the current market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for Companion Diagnostics market growth in the coming future?

Target Audience who can be benefited from the Companion Diagnostics Market Report Study

  • Companion Diagnostics providers
  • Research organizations and consulting companies
  • Companion Diagnostics-related organization, association, forum, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders in Companion Diagnostics
  • Various End-users want to know more about the Companion Diagnostics Market and the latest technological developments in the Companion Diagnostics market.

Frequently Asked Questions for the Companion Diagnostics Market:

1. What are Companion Diagnostics?

A companion diagnostic is a medical device, often an in vitro device, which provides information that is essential for the safe and effective use of a corresponding drug or biological product.

2. What is the market for Global Companion Diagnostics?

The global companion diagnostics market was valued at USD 5.91 billion in 2023, growing at a CAGR of 12.32% during the forecast period from 2024 to 2030, to reach USD 11.89 billion by 2030.

3. What are the drivers for Global Companion Diagnostics?

The major factors driving the demand for Companion Diagnostics are the exponential rise in cancer cases across the globe. Additionally, the rise in awareness regarding precision medicine among the patient population as well as the growing focus of the manufacturers concerning the development of precision medicine has bolstered the demand for companion diagnostics. Furthermore, an increase in research and development for developing companion diagnostics for non-cancer disorders, and growing approvals and launches of various companion diagnostic products in the market, among others are some of the key factors anticipated to augment the global market for companion diagnostics during the forecast period (2024-2030).

4. Who are the key players operating in Global Companion Diagnostics?

Some of the key market players operating in the Companion Diagnostics market include Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Abbott Laboratories., QIAGEN, BIOMERIEUX, Guardant Health Inc., Illumina, Inc., Pillar Biosciences, Inc., Leica Biosystems, Thermo Fisher Scientific Inc., Almac Group, NeoGenomics Laboratories., Invitae Corporation, 3D Medicines Corporation, ASURAGEN, INC. (Biotechne), Invivoscribe, Inc., Amoy Diagnostics Co., Ltd., Laboratory Corporation of America? Holdings., SAGA Diagnostics, and others.

5. Which region has the highest share in the Companion Diagnostics market?

Among all the regions, North America is expected to hold a major share in the overall Companion Diagnostics market in the year 2023 and will retain its market position during the forecast period. This is due to the rising prevalence and incidence of various cancers in the region. Moreover, favorable reimbursement policies, approval & launches of various companion diagnostic products in the region, various business expansion activities underwent by the companies present in the region, and others are some of the factors responsible for the companion diagnostics market.

Table of Contents

1.Companion Diagnostics Market Report Introduction

2.Companion Diagnostics Market Executive summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Companion Diagnostics Market Key factors analysis

  • 4.1. Companion Diagnostics Market Drivers
    • 4.1.1. The rise in cancer cases across the globe
    • 4.1.2. Increase in the demand and awareness regarding precision medicines
    • 4.1.3. Growing approval and launches of various companion diagnostic products
    • 4.1.4. Rise in research and development in the companion diagnostics field
  • 4.2. Companion Diagnostics Market Restraints and Challenges
    • 4.2.1. The high cost of companion diagnostics coupled with limited reimbursement in many countries
    • 4.2.2. Complex regulatory process for approval of companion diagnostic products
  • 4.3. Companion Diagnostics Market Opportunities
    • 4.3.1. Market opportunity in low and middle-income nations
    • 4.3.2. Opportunity of companion diagnostics in various non-cancer disorders

5. Companion Diagnostics Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Companion Diagnostics Market

7. Companion Diagnostics Market layout

  • 7.1. By Type
    • 7.1.1. Product
      • 7.1.1.1. Assay, Kits & Reagents
      • 7.1.1.2. Instruments
    • 7.1.2. Services
  • 7.2. By Technology
    • 7.2.1. Immunohistochemistry
    • 7.2.2. Next Generation Sequencing (NGS)
    • 7.2.3. Polymerase Chain Reaction (PCR)
    • 7.2.4. Others
  • 7.3. By Indication
    • 7.3.1. Lung Cancer
    • 7.3.2. Breast Cancer
    • 7.3.3. Colorectal Cancer
    • 7.3.4. Others
  • 7.4. By End-user
    • 7.4.1. Hospitals
    • 7.4.2. Diagnostic Labs
    • 7.4.3. Others
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States
      • 7.5.1.2. Canada
      • 7.5.1.3. Mexico
    • 7.5.2. Europe
      • 7.5.2.1. France
      • 7.5.2.2. Germany
      • 7.5.2.3. United Kingdom
      • 7.5.2.4. Italy
      • 7.5.2.5. Spain
      • 7.5.2.6. Russia
      • 7.5.2.7. Rest of Europe
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China
      • 7.5.3.2. Japan
      • 7.5.3.3. India
      • 7.5.3.4. Australia
      • 7.5.3.5. South Korea
      • 7.5.3.6. Rest of Asia Pacific
    • 7.5.4. Rest of the World (RoW)
      • 7.5.4.1. Middle East
      • 7.5.4.2. Africa
      • 7.5.4.3. South America

8. Companion Diagnostics Global Company Share Analysis - Key 3-5 Companies

9. Companion Diagnostics Company and Product Profiles

  • 9.1. Agilent Technologies, Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4. Product Listing
    • 9.1.5. Entropy
  • 9.2. F. Hoffmann-La Roche Ltd
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4. Product Listing
    • 9.2.5. Entropy
  • 9.3. Myriad Genetics, Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4. Product Listing
    • 9.3.5. Entropy
  • 9.4. Abbott Laboratories.
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4. Product Listing
    • 9.4.5. Entropy
  • 9.5. QIAGEN
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4. Product Listing
    • 9.5.5. Entropy
  • 9.6. BIOMERIEUX
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4. Product Listing
    • 9.6.5. Entropy
  • 9.7. Guardant Health Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4. Product Listing
    • 9.7.5. Entropy
  • 9.8. Illumina, Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4. Product Listing
    • 9.8.5. Entropy
  • 9.9. Leica Biosystems
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4. Product Listing
    • 9.9.5. Entropy
  • 9.10. Thermo Fisher Scientific Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4. Product Listing
    • 9.10.5. Entropy
  • 9.11. Almac Group
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4. Product Listing
    • 9.11.5. Entropy
  • 9.12. NeoGenomics Laboratories.
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4. Product Listing
    • 9.12.5. Entropy
  • 9.13. Invitae Corporation
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4. Product Listing
    • 9.13.5. Entropy
  • 9.14. 3D Medicines Corporation
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4. Product Listing
    • 9.14.5. Entropy
  • 9.15. ASURAGEN, INC. (Biotechne)
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4. Product Listing
    • 9.15.5. Entropy
  • 9.16. Invivoscribe, Inc.
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4. Product Listing
    • 9.16.5. Entropy
  • 9.17. Amoy Diagnostics Co., Ltd.
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4. Product Listing
    • 9.17.5. Entropy
  • 9.18. Laboratory Corporation of America® Holdings.
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4. Product Listing
    • 9.18.5. Entropy
  • 9.19. SAGA Diagnostics
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4. Product Listing
    • 9.19.5. Entropy
  • 9.20. Pillar Biosciences, Inc.
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4. Product Listing
    • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us